ClinicalTrials.gg

Program

imeroprubart

Also written as “IMVT-1402” and “Imeroprubart”.

Its studies are mostly in Graves Disease · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Myasthenia Gravis · Lupus Erythematosus, Cutaneous · Arthritis, Rheumatoid, led by Immunovant Sciences.

Furthest: phase 3, since Jun 18, 20258 company-led studies, 8 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immunovant Sciences88 open or runningphase 3since Jun 18, 2025Dec 9, 2024May 2027phase 2 · NCT07018323

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2024First studies: 2 phase 2 studiesFirst studyNCT06727604, NCT06754462
  2. May 8, 20253 phase 2 studiesNCT06980805, NCT06979531, NCT07018323
  3. Jun 11, 2025Phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07032662 · 162 planned · United States, Argentina, Australia and more
  4. Jun 18, 2025Phase 3 study in Myasthenia GravisNCT07039916 · 231 planned · United States, Argentina, Czechia and more
  5. Dec 10, 2025Phase 2 study in Graves DiseaseNCT07286006 · 372 planned · United States, Australia, Bulgaria and more

Ahead

  1. May 2027Primary completion: phase 2 study in Graves DiseaseNCT07018323
  2. Sep 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT06754462
  3. Dec 2027Primary completion: phase 3 study in Myasthenia GravisNCT07039916
  4. Jun 2028Primary completion: phase 2 study in Graves DiseaseNCT06727604

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07286006Graves Disease · United States, Australia, Bulgaria and more2By invitationMar 2030372
NCT07039916Myasthenia Gravis · United States, Argentina, Czechia and more3RecruitingDec 2027231
NCT07032662Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more2RecruitingAug 2028162
NCT07018323Graves Disease · United States, Australia, Brazil and more2RecruitingMay 2027210
NCT06979531Primary Sjögren's Syndrome · United States, Argentina, Canada and more2Active, not recruitingJul 2028180
NCT06980805Lupus Erythematosus, Cutaneous · United States, Argentina, Bulgaria and more2Active, not recruitingOct 202656
NCT06754462Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more2Active, not recruitingSep 2027120
NCT06727604Graves Disease · United States, Belgium, Georgia and more2RecruitingJun 2028240

How it is read

Names in the registry

  • “IMVT-1402”, 11 entries
  • “Imeroprubart”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.